Antiarrhythmic drugs in the management of atrial fibrillation

Antiarrhythmic drug therapy in the post-CAST era has undergone a period of uncertainty and re-evaluation. The role of antiarrhythmic drugs in the management of less serious arrhythmias has come into question. If an arrhythmia is not life-threatening it is paramount that it should not be made so through inappropriate treatment. This issue is particularly pertinent to the management of atrial fibrillation—the commonest of arrhythmias and one which in the absence of pre-excitation is not directly life-threatening. Yet the symptomatic limitations and morbidity imposed by atrial fibrillation are often severe and the need for effective and safe treatment is self-evident.

Restoration of sinus rhythm
In patients with recent onset of atrial fibrillation, sinus rhythm can often be restored pharmacologically. Digitalis, the traditional treatment, does not have a primary anti-fibrillatory action. On the contrary digitalis glycosides through their vagomimetic effects might be expected to be pro-fibrillatory. Not surprisingly, therefore, digoxin has been found to be no more effective than placebo in reverting atrial fibrillation to sinus rhythm.

In contrast class I and class III drugs in the Vaughan Williams classification do have a direct anti-fibrillatory action. Treatment is most successful in patients with recent onset of atrial fibrillation. Intravenous flecainide, for example, converted 60–80% of patients with recent onset atrial fibrillation to sinus rhythm and intravenous amiodarone converted 70–80%. Treatment is not without potential problems. Class I agents can adversely affect ventricular function or induce a slow atrial flutter with 1 to 1 conduction into the ventricle. Intravenous amiodarone can cause hypotension. However, unlike long-term antiarrhythmic therapy these risks are immediate and are not a major hazard when the physician is both aware and vigilant.

In appropriately selected patients antiarrhythmic treatment is therefore a reasonable alternative to DC cardioversion. It would be unwise, however, to advocate that class I or class III agents should completely replace digitalis in the management of new onset atrial fibrillation. In some patients there is no immediate need to restore sinus rhythm and ventricular rate control alone may be adequate: digitalisation is still appropriate for this purpose.

Maintenance of sinus rhythm
Digoxin is ineffective in preventing recurrences of atrial fibrillation. In contrast, both class I and class III agents are of value. When one specific drug fails there is still a case for assessing other agents because the arrhythmogenic mechanisms underlying atrial fibrillation vary from patient to patient and result in different responses to different drugs.

Quinidine, for many years the traditional therapy in the United States, is of proven efficacy—but at a cost. The dangers of torsades de pointes when treatment starts are well recognised and meta-analysis has suggested the possibility of an excess mortality in patients on quinidine therapy. It is questionable, therefore, whether a role for quinidine in the prophylaxis of atrial fibrillation can still be justified.

The class Ic agents flecainide and propafenone are gaining in popularity for prophylaxis. Once again their efficacy is proven, but can we be equally convinced about their safety? It is clear that we should avoid giving class Ic drugs to patients who resemble those recruited to CAST. Unfortunately, it is unclear which features of CAST patients predisposed them to arrhythmias. We do not know whether risks are confined to the particular patient population studied—that is, to patients with previous myocardial infarction and frequent ventricular extrasystoles—or whether they extend to all patients with previous infarction, coronary disease, or indeed any form of structural heart disease. Many patients with atrial fibrillation have underlying myocardial or coronary disease and it cannot be asserted that class Ic therapy carries no risk. Serious ventricular arrhythmias and sudden death have been reported in the management of supraventricular arrhythmias, including atrial fibrillation.

In contrast, class III antiarrhythmic therapy is also of proven value in prophylaxis. The archetypal agent, amiodarone, is particularly effective but has gained notoriety on account of its high incidence of side effects and occasional cases of pulmonary fibrosis. Whether this reputation is fully deserved in the management of atrial fibrillation is open to question because many patients are satisfactorily controlled on low doses of amiodarone of 200 mg daily or less. At these doses, though less serious side effects are still common, serious side effects are rare. The risks of proarhythmia are substantially less with amiodarone than with other antiarrhythmic agents.

Sotalol is gaining in popularity as an acceptable alternative to amiodarone. The recent success of sotalol in comparison with other antiarrhythmic agents in the management of serious ventricular arrhythmias in the ESVEM study adds to the general attractions of this drug. The drug is as effective as quinidine in prophylaxis. Even sotalol, however, carries a proarhythmic risk, and may induce torsades de pointes. The extent to which the antiarrhythmic benefits of sotalol are related to its class III action is open to question because the doses required to achieve β blockade and to prolong repolarisation are not equivalent. At low doses β blockade predominates and it is possible that antiarrhythmic benefits merely reflect this action. If so, other
Control of ventricular rate

The limitations of digoxin for rate control in atrial fibrillation are well recognised. Digoxin has little effect on peak heart rate at maximum exercise. 34 β Blockers, in contrast, do limit heart rate at peak exercise. Somewhat disappointingly, however, this has generally not been reflected in an improvement in exercise tolerance. 35,36 Because of this and because of the difficulties of using β blockers in patients who often have underlying ventricular impairment, digoxin continues to be a mainstay of treatment. When digoxin alone proves inadequate, the addition of a β blocker or calcium antagonist can prove synergistic in improving the rate control. 37 The partial β agonist xamoterol, which initially held much promise in the treatment of atrial fibrillation, 38,39 has fallen into disfavour because of the increased mortality associated with its use in patients with heart failure. 40

The future

Whereas the limitations of drug therapy in the management of atrial fibrillation are readily apparent the successes should also be recognised. The success of newer treatments poses a particular problem because the risks of therapy are so ill-defined. It cannot be denied that treatment carries the potential for an increased mortality, yet there may also be prognostic benefits in successful drug treatment. Maintenance of sinus rhythm may reduce the thromboembolic risk. Superior rate control may prevent deterioration of left ventricular function. 41,42 Whatever the net effect on prognosis, withholding treatment may condemn patients to an unnecessary morbidity.

The ideal would be to develop new antiarrhythmic drugs without proarrhythmic risk. This is fundamentally not achievable because the same properties that protect against arrhythmias in some patients will cause them in others. 43 Considerable research is currently being directed to the development of new class III agents, which it is hoped will offer the benefits of amiodarone without its side effects. Several drugs are being evaluated. The question remains whether future class III agents will carry a greater risk of torsades de pointes than amiodarone. This issue is of particular importance in the management of atrial fibrillation. While some risk of proarrhythmia might be acceptable in the management of life-threatening ventricular arrhythmias, a similar risk would be unacceptable in the management of atrial fibrillation.

It is possible therefore that future antiarrhythmic drugs will confer no advantages over those currently available. For this reason, we need to define more precisely the risks and benefits of available drugs. Recent well-controlled studies of warfarin and aspirin treatment in patients with atrial fibrillation have led the way and clarified the benefits and risks of anticoagulation. 44 A similar approach is now needed with antiarrhythmic treatment.

33 Flaker GC, Blackhauser JL, McBride R, Kronnal RA, Halperin JL,


Molajo AO, Coupe MO, Bennett DH. Effect of Corwin (ICI 118587) on resting and exercise heart rate and exercise tolerance in digitalized patients with chronic atrial fibrillation. Br Heart J 1984;52:392-5.


Antiarrhythmic drugs in the management of atrial fibrillation.

J C Cowan

Br Heart J 1993 70: 304-306
doi: 10.1136/hrt.70.4.304

Updated information and services can be found at:
http://heart.bmj.com/content/70/4/304.citation

These include:
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to: http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to: http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to: http://group.bmj.com/subscribe/